Posted on 19/06/2009 in Pharmaceutical Company Product News Sanofi-Aventis intends to appeal a court decision over its chemotherapy medication, it has stated.
By granting summary judgement motions brought by a number of generic firms in the Eloxatin (oxaliplatin) patent litigation, the district court of New Jersey ruled against the company.
The pharmaceutical business asserted: "Sanofi-Aventis is not modifying its 2009 guidance as a result of this court order."
As well as acting as the adjacent treatment of stage III cancer, Eloxatin is also used to manage metastatic colorectal cancer.
It was decided Hospira's version of the drug does not infringe Sanofi-Aventis' patent.
Vice-president of the former firm Joshua Gordon asserted the company is "extremely pleased" with the ruling.
He added the launch of its oxaliplatin injection would provide a lower-cost and high-quality treatment alternative to patients.
Mr Gordon concluded the medication was an example of Hospira's commitment to meet patient and caregiver needs in the oncology market, which is expanding quickly.Other news stories from 19/06/2009
Read more in the Zenopa News Archive
How this news is generated
|
